罗沙司他对维持性血液透析患者肌少症的影响研究  

The effect of roxadustat on sarcopenia in patients with maintenance hemodialysis

作　　者：蒋传芹 王爱英[2] Jiang Chuanqin;Wang Aiying(Department of Hemodialysis Room,Linyi Central Hospital,Linyi 276401,China;Binzhou Medical University,Yantai 271400,China)

机构地区：[1]临沂市中心医院血液透析室,临沂276401 [2]滨州医学院,烟台271400

出　　处：《国际泌尿系统杂志》2025年第1期143-146,共4页International Journal of Urology and Nephrology

摘　　要：目的探讨罗沙司他对维持性血液透析患者肌少症的治疗作用,为临床肌少症的治疗提供理论依据。方法收集2022年6月至2023年6月本院收治的行维持性血液透析且病情较稳定的72例肌少症患者的临床资料,根据不同治疗方式将患者分为罗沙司他组(36例)和促红细胞生成素组(36例)。检测两组患者治疗前后的肌少症诊断指标,包括骨骼肌质量指数(SMI)、握力(HGS)、6 m行走速度和简易体能状况量表(SPPB)。结果治疗前促红细胞生成素组和罗沙司他组患者的SMI[男:(5.8±1.13)kg/m^(2) vs.(5.7±1.06)kg/m^(2);女:(4.88±1.02)kg/m^(2) vs.(4.96±1.15)kg/m^(2)]、HGS[男:(24.8±2.19)kg vs.(25.1±2.13)kg;女:(15.2±1.63)kg vs.(14.9±1.83)kg]、6 m行走速度[(0.84±0.11)m/s vs.(0.85±0.13)m/s]和SPPB评分[(6.75±0.87)分vs.(6.85±0.79)分]比较,差异均无统计学意义(均P>0.05)。而治疗后,相对于促红细胞生成素组,罗沙司他组患者的SMI[男:(-1.12±0.12)kg/m^(2) vs.(-0.67±0.13)kg/m^(2);女:(-0.98±0.09)kg/m^(2) vs.(-0.52±0.08)kg/m^(2)]、HGS[男:(-2.12±0.15)kg vs.(-1.08±0.16)kg;女:(-1.84±0.16)kg vs.(-0.98±0.12)kg]、6 m行走速度[(-0.19±0.03)m/s vs.(-0.10±0.02)m/s]和SPPB评分[(-1.69±0.20)分vs.(-0.89±0.30)分]降低情况显著减轻,差异均有统计学意义(均P<0.05)。此外,与促红细胞生成素组比较,罗沙司他治疗组患者的跌倒人次显著减少(均P<0.05)。结论罗沙司他能够显著延缓维持性血液透析患者肌少症的病情进展,本研究为临床上肌少症的治疗提供了一定的理论依据。Objective To investigate the therapeutic efficacy of roxadustat in managing sarcopenia among maintenance hemodialysis patients,and to establish a theoretical foundation for clinical treatment of sarcopenia.Methods The clinical data of 72 patients with sarcopenia and stable condition who underwent maintenance hemodialysis were collected at our hospital from June 2022 to June 2023.Based on different treatment methods,the patients were divided into two groups:the roxadustat group(36 cases)and the erythropoietin group(36 cases).The diagnostic indicators of sarcopenia,including skeletal muscle mass index(SMI),grip strength(HGS),6-meter walking speed and Simple Physical Performance Battery(SPPB),were examined before and after treatment.Results There was statistically significant difference in the SMI[Male:(5.8±1.13)kg/m^(2) vs.(5.7±1.06)kg/m^(2);female:(4.88±1.02)kg/m^(2) vs.(4.96±1.15)kg/m^(2)]and HGS[male:(24.8±2.19)kg vs.(25.1±2.13)kg;female:(15.2±1.63)kg vs.(14.9±1.83)kg],6 m travel speed[(0.84±0.11)m/s vs.(0.85±0.13)m/s]and SPPB[(6.75±0.87)min vs.(6.85±0.79)min]between the roxadustat group and erythropoietin group before treatment.There were no significant differences(all P>0.05).After treatment,compared with the erythropoietin group,the SMI of patients in the roxadustat group[male:(-1.12±0.12)kg/m^(2) vs.(-0.67±0.13)kg/m^(2);female:(-0.98±0.09)kg/m^(2) vs.(-0.52±0.08)kg/m^(2)),HGS[Male:(-2.12±0.15)kg vs.(-1.08±0.16)kg;female:(-1.84±0.16)kg vs.(-0.98±0.12)kg],6 m walking speed[(-0.19±0.03)m/s vs.(-0.10±0.02)m/s]and SPPB[(-1.69±0.20)points vs.(-0.89±0.30)points]was significantly reduced,and the differences were statistically significant(all P<0.05).In addition,compared with erythropoietin group,the number of falls and mortality were significantly reduced in the roxadustat group(all P<0.05).Conclusions Roxadustat can significantly retard the progression of sarcopenia in patients with maintenance hemodialysis.Our founding provides a theoretical basis for the treatment of sarcopenia in clinical

关 键 词：肾透析 罗沙司他 肌少症 

分 类 号：R692.5[医药卫生—泌尿科学] R685[医药卫生—外科学]